Latest News - Headache & Pain

Friday, May 04, 2018

OnabotulinumtoxinA for Migraine Has Long-Term Safety and Efficacy

A wealth of results showing the long-term safety and efficacy of onabotulinumtoxinA (Botox; Allergan, Dublin, Ireland) for treating patients with migraine were presented at the recent American Academy…

Read the full story

Wednesday, May 02, 2018

Noninvasive, Cost-Effective Neuromodulation Therapy for Migraine and Cluster Headache

At the recent American Academy of Neurology meeting in Los Angeles, CA, electroCore, a commercial-stage bioelectronic medicine company, presented data from the PRESTO study of a hand-held noninvasive …

Read the full story

Sunday, April 22, 2018

Phase 3 Results for Ubrogepant for Treatment of Patients With Migraine

At the American Academy of Neurology meeting in Los Angeles, CA, researchers Joel Trugman, Michell Finnegan, Richard Lipton and others presented results from a phase 3 study on ubrogepant (Allergan, D…

Read the full story

Tuesday, April 17, 2018

Results from Phase 3 Trial of Erenumab for Migraine

Results were announced today from the phase 3b LIBERTY trial treating patients with migraine who have not had relief from 2 to 4 other treatment options with erenumab (provisionally approved as Aimovi…

Read the full story

Wednesday, March 07, 2018

Biomarkers Available to Speed Diagnosis of Fibromyalgia

Iquity (Nashville, Tennessee) has announced the release of IsolateFibromyalgia, an RNA analysis of blood samples, for the fast and accurate detection of fibromyalgia syndrome. IsolateFibromyalgia s…

Read the full story

Tuesday, March 06, 2018

First Patient Enrolled in Phase 3 Clinical Trial of Rimegepant for Acute Migraine Treatment

Biohaven Pharmaceutical (New Haven, CT) announced today the first patient enrollment in their phase 3 clinical trial of rimegepant (Zydis) for the acute treatment of migraine.  Zydis is an orally…

Read the full story

Thursday, March 01, 2018

Biosimilar Being Developed for Botox

In a transatlantic collaboration, Mylan N.V. (Pittsburgh, Pennsylvania) and Revance Therapeutics, Inc. (Hertsfordshire, England) have reached an agreement to collaborate on the development and commerc…

Read the full story

Tuesday, February 20, 2018

Migraine Sufferers May Be at Greater Risk of Ischemic Stroke

Stroke, a journal of the American Heart Association published an article by Alessandro Pezzine, Giorgio Busto, Marialuisa Zedde, et al., (Stroke. 2018:published online Feb 20) suggesting that migraine…

Read the full story

Thursday, January 25, 2018

First Prospective Registry Shows Efficacy of Neuromodulation of the Sphenopalatine Ganglion for Treating Cluster Headache

On January 25, 2018, The Journal of Headache and Pain published one-year results from an open-label registry trial, Pathway R-1, evaluating the efficacy of sphenopalatine-ganglion stimulation (SPGs) (…

Read the full story

Monday, January 08, 2018

PROMISE Phase 3 Trial for Chronic Migraine Prevention Meets Primary and All Key Secondary Endpoints; Shows Reduction in Migraine Risk

January 8, 2018--Alder Biopharmaceutical reported that their injectable calcitonin-gene-related peptide (CGRP)-inhibitor eptinezumab, in phase 3 clinical trials, reduced monthly migraine days by 50% o…

Read the full story

Thursday, October 12, 2017

Once-Daily Lyrica Formulation Wins FDA Approval

The FDA has approved Lyrica CR (pregabalin, Pfizer) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and t…

Read the full story

Wednesday, September 20, 2017

FDA Approves Intellis Device for Intractable Pain

The FDA has approved the Intellis platform (Medtronic) for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitations with current spinal c…

Read the full story

Tuesday, August 01, 2017

Non-Invasive Neuromodulation Device for Chronic Intractable Pain Cleared by FDA

The FDA has cleared the Stimpod NMS460 (Xavant Technology), a non-invasive neuromodulation device for the symptomatic relief and management of chronic intractable pain. When applied to the affected ar…

Read the full story

Tuesday, June 13, 2017

AHS 2017: Amgen’s CGRP Inhibitor Reduces Migraine Days

New Phase 2 data show that Amgen’s investigational investigational CGRP inhibitor erenumab is effective at preventing migraine in patients experiencing 15 or more migraine days per month. In a s…

Read the full story

Thursday, June 08, 2017

AHS 2017 Meeting: Prochlorperazine More Effective than Hydromorphone for Acute Migraine

A new comparative study presented at the American Headache Society Annual Meeting in Boston shows that that, in patients who visit the emergency department for acute migraine treatment, prochorperazin…

Read the full story
Load More